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when considering how to promote health by linking agriculture, food and nutrition, it makes perfect sense to have a closer look at existing legisla-tion in the area of nutrition and health claims made on food products. This 
is particularly important because what industry is allowed to say about the impact on 
health of the foods it sells is an essential element in a number of areas, such as consumer 
awareness, consumer education, product research and development, and research-funding 
opportunities. after all, why would anyone invest considerable resources to do research, 
develop and market a particular food product that would be more nutritious or would 
help mitigate certain disease-risk factors, if the law were to prohibit any commercial 
communication on those health benefits? 
when examining existing legislation on nutrition and health claims made on foods, it 
is also useful to consider the regulatory framework in the european Union (eU). There 
are three main reasons for that. firstly, the eU is certainly one of the most regulated 
regions in the world, particularly in the food area, and it tries to “export”—or at least 
promote—its regulatory options to other regions and countries worldwide. food legis-
lation adopted in the eU tends to inspire regulators in other countries. Secondly, eU 
food laws, in general, tend to be more restrictive than in other regions. Thirdly, the eU 
legislation on nutrition and health claims was adopted recently and some of its provisions 
are still being developed, causing considerable controversy. Therefore, keeping an eye on 
the developments in the eU in terms of food claims will help promote understanding of 
what food manufacturers will be able to communicate to consumers in the eU as well as 
what new regulatory “tools” could potentially be replicated in other countries.
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The eU regulation on nutrition and Health Claims [regulation (eC) no 9/00], 
hereafter “the regulation,” has certainly been one of the most controversial pieces of 
legislation of the last decade in the area of eU food law. Its significant impact—current 
and future—on the food industry, particularly on functional foods and food supplements, 
has made its gradual implementation remarkably complex and contentious. In addition, 
some of its provisions, such as nutrient profiles, have raised such significant opposition 
from industry that its ongoing implementation has constantly been the subject of ex-
tensive press coverage, with a number of tough political and technical debates, since its 
adoption in December 00.
Before the adoption of this legislation, various national legal frameworks regulated the 
use of nutrition and health claims across the eU. Some Member States had strict rules 
whereas others relied only on very general principles. In certain cases, the differences 
among national provisions were obstacles to the free movement of food products within 
the eU market. This situation also created significant distortions of competition on the 
market. This explains why the food industry itself was one of the main entities asking 
eU regulators to harmonize legislation in this area. 
Scope and objectives of the regulation
The regulation became applicable on July , 00, across all twenty-seven eU Member 
States. In principle, the same rules are now applicable to all companies selling their 
products in the eU market, including imported products.
The regulation applies to all nutrition and health claims made in all “commercial com-
munications.” These include not only claims made on product labels, but also claims made 
in advertising (television, radio, etc.), websites, promotional leaflets, on-shelf presentations, 
etc. any communication on the nutritional or health benefits of a food product made on 
any commercial entity must comply with the provisions of the regulation.
when proposing and adopting this legislation, the eU regulators intended to achieve 
three main objectives:
• to ensure a high level of protection for consumers. This would be achieved 
through measures aiming at ensuring that all claims are scientifically substanti-
ated, and also through provisions intended to avoid the over-consumption of 
certain products due to the claims they would make. 
• to facilitate consumer choice. a clear set of rules applying across the eU, with 
strict conditions and specific restrictions would allow consumers to make their 
purchases knowing that the claims made on the products they would buy are 
meaningful and scientifically justified. 
• to ensure the effective functioning of the internal market. Similarly, the same 
rules applying to all twenty-seven national markets would lead to equal condi-
tions of competition for the food industry while enabling the free movement of 
food products across the eU.
to achieve these objectives, the regulation is based on two key principles:
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• All nutrition and health claims must be approved at EU level. 
• Certain foods will be prohibited from nutrition and/or health claims.
all Claims Must be approved at eU Level
The regulation defines two general types of claims—“nutrition claims” and “health 
claims”—which are approved through different authorization procedures. nutrition 
claims are defined in the regulation as “any claim suggesting that a food has particular 
beneficial nutritional properties due to the energy, nutrients, or other substances it con-
tains, contains in reduced or increased proportions or does not contain.” Health claims 
are defined as “any claim suggesting that a relationship exists between a food category, a 
food or one of its constituents and health.”
The key principle laid down in the regulation is that all nutrition or health claims 
must be approved at the eU level through the applicable procedures and be included 
in a positive list. only the claims mentioned in the eU positive lists will be permitted 
in the eU. 
Permitted Nutrition Claims
The regulation itself includes, in its annex, a positive list of the permitted nutrition claims 
(table ). Since January 9, 00, these have been the only permitted nutrition claims 
in the eU market. all others are prohibited, including certain nutrition claims that have 
been widely used across the eU until recently, such as “high energy,” “cholesterol free,” 
“extra light,” “trans-fat free” and “high in omega- fatty acids.”
Source of fiber
High fiber
Source of protein
High protein
Source of [name of vitamin(s)] and/or [name of mineral(s)]
High [name of vitamin(s)] and/or [name of mineral(s)]
Contains [name of the nutrient or other substance]
Increased [name of the nutrient]
reduced [name of the nutrient]
Light/lite
naturally/natural (as a qualifier for other nutrition claim,
e.g. “naturally high in fibre”)
Low energy
energy reduced
energy free
Low fat
fat free
Low saturated fat
Saturated-fat free
Low sugar
Sugar free
with no added sugars
Low sodium/salt
very low sodium/salt
Sodium free or salt free
Table 1. lisT of permiTTed nuTriTion claims in The eu.
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The annex to the regulation includes specific conditions of use that must be complied 
with in order for a food product to bear a particular nutrition claim. as an example, a 
claim that a food is “fat free” may be made only if the product contains no more than 0.5 
g of fat per 00 g or 00 mL. also, claims expressed as “X% fat free” are prohibited.
This positive list of permitted nutrition claims may be amended to take into account 
scientific and technological developments. a first amendment was adopted in february 
00 [Commission regulation (eU) no /00] with the addition of five more per-
mitted nutrition claims on fatty acids: “source of omega-3 fatty acids”; “high in omega-3 
fatty acids”; “high in mono-unsaturated fat”; “high in poly-unsaturated fat”; and “high 
in unsaturated fat.”
as it stands, the annex on nutrition claims is generally considered to be very restric-
tive. for example, claims relating to cholesterol (“cholesterol free,” “low in cholesterol”) 
are not included, although they were popular with certain consumers. Their inclusion 
in the positive list had been requested by industry and a number of Member States, but 
the regulators decided in the end not to authorize them because they were regarded as 
potentially misleading. It was feared that consumers did not understand the difference 
between dietary cholesterol and blood cholesterol, and the small impact the former has on 
the latter. another example of a “popular” nutrition claim that has not been included in 
the positive list is “high energy.” The fact that this claim, and any claim having the same 
meaning, is not authorized in the eU has considerable implications on sports foods, for 
example. a large number of product concepts, such as energy bars, energy gels and sports 
beverages have been severely affected by this decision. 
Certainly, one of the most restrictive aspects of the regulation, in relation to nutrition 
claims, is the very limited number of permitted comparative nutrition claims and the 
conditions applying to them. as it currently stands, the regulation authorizes only four 
comparative nutrition claims: “energy-reduced,” “increased [name of nutrient],” “reduced 
[name of nutrient]” and “light/lite.” one of the conditions of use for these four claims is 
that there must be a difference in the content of the nutrient in question of at least 30% 
between the products being compared. This is clearly a challenge for food manufacturers 
carrying out reformulation programmes, as reducing the content of certain nutrients by 
30% is difficult to achieve and, in certain cases—such as salt reduction—it may even 
lead to consumer rejection of the new recipe. This restrictive condition, particularly for 
reduction claims, is seen as a missed opportunity for eU regulators to give an incentive 
to industry to reformulate their products. By raising the bar too high, the regulators may 
have discouraged certain companies from improving their product recipes; why would 
a company reformulate its products at great cost if the law does not allow those efforts 
to be communicated to consumers? are reductions in fat, saturated fat, salt or sugar of 
5% or 0% really irrelevant? 
Permitted Health Claims?
Contrary to the situation for nutrition claims, the regulation itself does not include 
a positive list of permitted health claims. However, it lays down specific provisions re-
quiring the establishment of such positive lists, as well as describing the corresponding 
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authorization procedures that must be followed to obtain authorization for different 
types of health claims. 
The regulation classifies health claims in three broad categories, to each of which dif-
ferent authorization procedures apply:
• nutrient-function claims, which include all claims referring to the growth, devel-
opment or the functions of the body (e.g. “calcium helps maintain strong teeth 
and bones”), as well as psychological and behavioral claims (e.g. “substance X 
helps improve concentration and memory”), and slimming and satiety claims (e.g. 
“substance Y helps you want to eat less/lose weight”). 
• reduction-of-disease-risk claims, which “state, suggest or imply that the con-
sumption of a food category, a food or one of its constituents significantly reduces 
a risk factor in the development of a human disease” (e.g. “substance Z has been 
shown to lower/reduce blood cholesterol. High cholesterol is a risk factor in the 
development of coronary heart disease”).
• Claims referring to children’s development and health. The regulation itself does 
not provide a definition for this category of health claims. However, guidance 
on the implementation of the regulation (Guidance on the Implementation of 
regulation no 9/00, 00) was adopted at a later stage, which clarified 
that this particular type of health claim would include: a) those solely referring to 
the development and health of children, and where the scientific substantiation is 
valid only for children, i.e. the scientific substantiation should result from stud-
ies conducted with children; b) those used on products intended exclusively for 
children, like follow-on formulae and cereal-based baby foods.
obtaining authorization for health claims and their subsequent inclusion in a positive 
list is possible through two different authorization processes that are currently operational 
in parallel.
Process 1—The Authorization Procedure for Nutrient-Function Claims 
that were Submitted for Approval by January 2008
The regulation established an authorization procedure for nutrient-function claims, 
whereby the Member States had to send to the european Commission, before the end 
of January 00, their national lists of proposed health claims. These lists included the 
proposed conditions of use for each claim, the proposed wordings and lists of scientific 
references substantiating the claims. The Commission compiled these national lists and 
sent them to the european food Safety authority (efSa) for a scientific evaluation, before 
establishing a Community list of permitted health claims. The regulation clarifies that 
until this list is established, claims submitted for approval through this procedure will be 
allowed to remain on the market until a final decision is adopted on them. 
The Commission was probably expecting a few hundred health claims to be tabled for 
adoption. However, the twenty-seven eU Member States submitted a total of 3,0. 
The process for collecting these claims differed from one country to another. for example, 
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one Member State submitted more than 0,000 claims, which had been proposed by its 
national food industry, whereas another Member State submitted only nine, which were 
the only ones that had officially been approved in the past by the national authorities. 
However, a considerable number of the claims submitted were essentially duplicates, as 
the same claims were often submitted by the same applicants in the different Member 
States where the claims were being used. with some time and effort, the Commission was 
able to reduce the list of proposed claims to ,3, by removing duplicates and deleting 
entries that were incomplete or inappropriate. 
efSa is now evaluating the scientific basis for these ,3 proposed health claims. Be-
cause the number of claims to be assessed remains quite high, efSa will publish the results 
of its assessment in several batches. to date, only two batches have been published, cover-
ing fewer than ,000 claims (table ). However, they indicate what should be expected 
from future evaluations, and what types of claims are likely to be approved or rejected in 
the eU. already, impact on the market is becoming clear, particularly for sectors such as 
probiotics, antioxidants and botanicals. The first efSa evaluations were mostly negative 
(% for the first batch, 9% for the second) with rejections of most claims submitted 
on probiotic bacteria/microorganisms, antioxidants, plant extracts/botanicals, and claims 
on carbohydrate glycemic index/response. The higher rate of positive evaluations in the 
first batch can be explained by the fact that these correspond essentially to claims for 
vitamins and minerals for which there has long been scientific consensus.
Table 2. efsa evaluaTions of nuTrienT-funcTion claims 
(To daTe)—arTicle 13.3.
Batch number
 1 2
Publication date october , 009 february 5, 00
number of claims 53  
processed
Substances involved vitamins & minerals antioxidants
 Dietary fibers Carbohydrates glycemic index/response
 fatty acids Probiotics/microorganisms
 Probiotic bacteria Botanicals and herbals
 other (chewing gum, Substances linked to joints health
 plant extracts, etc.) other (honey, stearic acid, guar gum, etc.)
Positive evaluations 33% %
negative evaluations % 9%
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approximately 3,50 additional nutrient-function claims await evaluation. Based on 
these efSa evaluations, the eU regulator will then need to officially approve or reject the 
proposed claims, and include the approved ones in a positive list. Due to the considerable 
number that remains to be evaluated, the authorization process is expected to take until 
0. although it is difficult to predict how many claims are likely to be approved in the 
end, one can guess that, based on the current trend of the efSa evaluations, the final list 
of permitted claims will comprise a few hundred rather than a few thousand. and some 
very popular claims currently on markets worldwide may not be included.
Process 2—The Authorization Procedures for Nutrient-Function Claims 
Submitted for Approval after January 2008, for Reduction of Disease-Risk 
Claims and for Claims referring to Children’s Development and Health.
In addition to the authorization procedure described above, the regulation provides the 
possibility of obtaining authorizations for other types of health claims on the basis of 
individual application dossiers, i.e. reduction of disease-risk claims and claims referring to 
children’s development and health. This applies also to “new” nutrient-function claims that 
were not submitted via a Member State before the end of January 00. These application 
dossiers will also be scientifically evaluated by efSa, and the claims will subsequently be 
approved or rejected by the european Commission. approximately 50 individual claim-
application dossiers have been submitted so far (some of which have been withdrawn), of 
which eleven have been officially authorized (tables 3a, b) and forty-five officially rejected. 
approximately 0 additional applications currently await evaluation. 
as is illustrated in table , around 0% of the individual claim applications assessed 
by efSa received a negative opinion. This confirms the strict evaluation standards being 
applied by efSa to evaluate the scientific evidence being put forward by applicants to 
substantiate their proposed claims. 
The outcomes so far of the two authorization processes mentioned above clearly illustrate 
that the scientific bases being tabled by applicants to justify their claims are not meeting 
the standards being applied by the efSa to evaluate their quality. as efSa is evaluating 
the evidence submitted in both processes using the same criteria, it is not surprising that 
recurring reasons are being given for negative evaluations in both processes. These are, 
essentially:
• weakness of the scientific evidence submitted, and 
• insufficient characterization of the substance for which the claim is made. 
a number of proposed claims were made for broad categories of foods (“dairy products,” 
“fruits,” “fruits and vegetables”) which typically include many products with a range of 
nutritional compositions and impacts on health. for example, efSa considers that it 
cannot approve claims relating to “dairy products” because this category includes many 
types of foods, from Camembert cheese to fat-free yoghurts. also, the studies submitted 
were focused only on certain dairy products. In efSa’s terms, the substance—“dairy 
products”—is not sufficiently characterized to allow validation of the scientific evidence 
submitted.
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Table 3a. healTh claims officially auThorized (To June 2010), based 
on individual applicaTion dossiers—arTicles 13.5 and 14.
Health claims referring to the reduction of a risk factor in the development 
of a disease [Article 14(1)(a)]
Nutrient/substance/food Claim Conditions/restrictions of use
Plant sterols/plant stanol esters
Plant sterols: sterols extracted 
from plants, free or esterified with 
food-grade fatty acids.
Plant stanol esters
Chewing gum sweetened with 
00% xylitol
Plant sterols and plant stanol 
esters have been shown to 
lower/reduce blood choles-
terol. High cholesterol is a risk 
factor in the development of 
coronary heart disease.
Plant sterols have been shown 
to lower/reduce blood choles-
terol. High cholesterol is a risk 
factor in the development of 
coronary heart disease.
Plant stanol esters have been 
shown to lower/reduce blood 
cholesterol. High cholesterol is 
a risk factor in the development 
of coronary heart disease.
Chewing gum sweetened with 
00% xylitol has been shown 
to reduce dental plaque. High 
content/level of dental plaque 
is a risk factor in the develop-
ment of caries in children.
Information to the consumer that the ben-
eficial effect is obtained with a daily intake 
of .5–. g plant sterols/stanols. reference 
to the magnitude of the effect may be made 
only for foods within the following cat-
egories: yellow fat spreads, dairy products, 
mayonnaise and salad dressings. when 
referring to the magnitude of the effect, the 
entire range “ to 0 %” and the duration 
to obtain the effect “in  to 3 weeks” must 
be communicated to the consumer.
Information to the consumer that the ben-
eficial effect is obtained with a daily intake 
of at least  g plant sterols. Information to 
the consumer that the beneficial effect is 
obtained with a daily intake of .5–. g 
plant sterols. reference to the magnitude 
of the effect may be made only for foods 
within the following categories: yellow fat 
spreads, dairy products, mayonnaise and 
salad dressings. when referring to the mag-
nitude of the effect, the entire range “ to 
0%” and the duration to obtain the effect 
“in  to 3 weeks” must be communicated 
to the consumer.
Information to the consumer that the ben-
eficial effect is obtained with a daily intake 
of .5–. g plant stanols. reference to the 
magnitude of the effect may be made only 
for foods within the following categories: 
yellow fat spreads, dairy products, mayon-
naise and salad dressings. when referring 
to the magnitude of the effect, the entire 
range “ to 0 %” and the duration to 
obtain the effect “in  to 3 weeks” must be 
communicated to the consumer.
Information to the consumer that the bene-
ficial effect is obtained with a consumption 
of –3g of chewing gum sweetened with 
00% xylitol at least three times per day 
after the meals.
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Table 3b. more healTh claims officially auThorized (To June 2010), 
based on individual applicaTion dossiers—arTicles 13.5 and 14.
Health claims referring to children’s development and health [Article 14(1)(b)]
Nutrient/substance/food Claim Conditions/restrictions of use
α-linolenic acid (aLa) & linoleic 
acid (La), essential fatty acids
Calcium and vitamin D
Calcium
vitamin D
Phosphorus
Protein
water-soluble tomato concentrate 
(wStC I and II)
essential fatty acids 
are needed for normal 
growth and develop-
ment of children.
Calcium and vita-
min D are needed for 
normal growth and 
development of bone 
in children.
Calcium is needed for 
normal growth and 
development of bone 
in children.
vitamin D is needed 
for normal growth and 
development of bone in 
children.
Phosphorus is needed 
for the normal growth 
and development of 
bone in children.
Protein is needed for 
normal growth and 
development of bone 
in children.
water-soluble tomato 
concentrate (wStC) 
I and II helps main-
tain normal platelet 
aggregation, which 
contributes to healthy 
blood flow.
Information to the consumer that the beneficial 
effect is obtained with a daily intake of  g of 
α-linolenic acid (aLa) and a daily intake of 0 
g of linoleic acid (La).
The claim can be used only for food which is 
at least a source of calcium and vitamin D as 
referred to in the claim SoUrCe of [naMe 
of vItaMIn(S)] anD/or [naMe of 
MIneraL(S)] as listed in the annex to regula-
tion 9/00.
The claim can be used only for food which is 
at least a source of calcium as referred to in the 
claim SoUrCe of [naMe of vItaMIn/S] 
anD/or [naMe of MIneraL/S] as listed in 
the annex to regulation 9/00.
The claim can be used only for food which is at 
least a source of vitamin D as referred to in the 
claim SoUrCe of [naMe of vItaMIn/S] 
anD/or [naMe of MIneraL/S] as listed in 
the annex to regulation 9/00.
The claim can be used only for food which is at 
least a source of phosphorus as referred to in the 
claim SoUrCe of [naMe of vItaMIn/S] 
anD/or [naMe of MIneraL/S] as listed in 
the annex to regulation 9/00.
The claim can be used only for food which is at 
least a source of protein as referred to in the claim 
SoUrCe of ProteIn as listed in the annex 
to regulation 9/00.
Information to the consumer that the beneficial 
effect is obtained with a daily consumption of 3 
g wStC I or 50 mg wStC II in up to 50 mL 
of either fruit juices, flavored drinks or yogurt 
drinks (unless heavily pasteurized).
Health claims based on newly developed scientific evidence [article 3(5)]
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another key lesson learned in recent years is that companies tend to be overoptimistic 
about the quality of their research and the strength of their application dossiers. Most 
applications were negatively evaluated by efSa because the scientific evidence submit-
ted did not include human-intervention studies. It was hoped by many that efSa could 
be persuaded to, in certain cases, refer to a grading of the available evidence to evaluate 
whether the data submitted supported the claims—“convincingly,” “possibly,” “probably,” 
or “insufficiently”—but efSa refuses to be persuaded and strictly applies its gold stan-
dard: human-intervention studies are a must to obtain a positive evaluation. Commission 
regulation (eC) no 353/00 clearly lays down, hierarchically, the levels of data that 
should ideally be included in an application dossier:
• Human data
 — Human-intervention studies, randomized controlled studies, other ran-
domized studies (non-controlled), controlled (non-randomized) studies, other 
intervention studies.
 — Human observational studies, cohort studies, case-control studies, cross-sec-
tional studies, other observational studies such as case reports.
 — other human studies dealing with the mechanisms by which the food could 
be responsible for the claimed effect, including the studies on bioavailability.
• non-human data
 — animal data including studies of aspects related to absorption, distribution, 
metabolism, excretion of the food, mechanistic studies, and other studies.
 — Ex vivo or in vitro data based on either human or animal biological samples 
related to mechanisms of action by which the food could be responsible for the 
claimed effect, and other non-human studies.
Table 4. efsa evaluaTions of individual claims applicaTion dossiers 
(To June 2010).
Type of claim Favorable Favorable with Issues raised Total
  limited conditions
new functional claims  –  
(article 3.5)
reduction of disease risk claims 5 – 0 5
(article )
Claims referring to children’s 
development and health   3 
(article )
total     5
 (%) (%) (9%) (00%)
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However, it is clear now that most of the studies mentioned above will be useful in an 
application dossier only if submitted as supporting evidence for well designed human-
intervention studies, without which there is very little chance of success. There is no 
grading of the available evidence.
a good illustration of the strict evaluation criteria being used by efSa is provided 
by its opinion on an application for a reduction-of-disease-risk claim on cranberry juice 
(european food Safety authority, 009a). The proposed claim was: “[the product] helps 
reduce the risk of urinary tract infection in women by inhibiting the adhesion of certain 
bacteria in the urinary tract”. efSa concluded that the evidence submitted by the applicant 
was insufficient to establish a cause-effect relationship between the consumption of the 
product in question and the claimed effect. although the application dossier contained 
a number of human studies, they were dismissed by efSa for the following reasons:
• Six human studies were judged of limited relevance because the claim targeted 
healthy women (aged  and above), whereas the studies were carried out on 
unhealthy subjects (patients suffering from neurogenic bladder) and children.
• In an additional human study the daily dose of the active substance consumed 
was approximately six times higher than the use levels proposed for the claim.
• although five other human-intervention studies were considered pertinent to the 
claimed effect, efSa criticized the two key randomized, placebo-controlled trials. 
The first one for its short duration and lack of statistical power, the second one for 
the lack of adequate randomization and high drop-out rate.
• The other three pertinent human studies were also criticized by efSa due to 
significant limitations, including the use of different cranberry formulations (ma-
trixes) from that in the application, poor study design, as well as high drop-out 
rates in some of the studies.
• It is also noteworthy that efSa did not consider meta-analyses and previous 
opinions by national food-safety authorities (on the same/similar claim) as rel-
evant evidence.
Interestingly, although efSa recognized a proven in vitro inhibitory effect on adhesion 
of E. coli to mucosal cells, it concluded nevertheless that the evidence submitted did not 
establish that the anti-adherence effects shown in vitro are predictive of the occurrence 
of a clinically relevant bacterial anti-adherence effect within the urinary tract under the 
conditions of use proposed for the claim. This claim was rejected by the european Com-
mission in november 009 (Commission regulation (eC) no /009). 
Based on the efSa evaluations so far, as well as on efSa’s guidance for the prepara-
tion of claim-application dossiers (european food Safety authority, 00, 009b), one 
can list key criteria that potential applicants should use to assess the strength of their 
application dossier (eaS, 00):
• Is the food or food constituent sufficiently characterized to the extent that it 
can be verified that the food or food constituent is the subject of the studies 
 performed and therefore responsible for the claimed effect?
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• are the studies carried out with the food or food constituent that is the subject of 
the claimed effect?
• are human studies available with appropriate outcome measures in relation to the 
claimed effect?
• are the conditions under which the food or food constituent is tested in the hu-
man studies representative for the proposed conditions of use for the claim (level 
of intake, pattern of consumption, etc.)?
• are the human studies or study group representative of the proposed target of the 
claim? Can the study results be extrapolated to the target population of the claim?
• Is a rationale available to explain how studies in animals or in vitro support the 
claimed effect in humans?
However, these criteria were “officially” disclosed only after a considerable number of 
applications had already been submitted (Processes  and  above). efSa’s evaluation 
criteria became clearer after its first detailed opinions had been published. for example, 
the level of characterization that efSa requires for microorganisms (probiotics) was clearly 
stipulated only after efSa had already evaluated (negatively) a considerable number of 
claims on probiotics.
needless to say, the extremely high rate of negative claim evaluations by efSa, and 
the expected subsequent rejection by the european Commission of the vast majority of 
the claims submitted for approval, were not greeted with joy by the food industry in the 
eU. Consequences for the food market will be considerable, particularly in the area of 
functional foods, food supplements and botanicals. Based on the efSa evaluations so far, 
it is fair to say that the mass rejections of most claims on antioxidants, probiotic bacte-
ria/microorganisms, botanicals/plant extracts, joint health and glycemic index/response 
are likely to lead to serious difficulties for those markets. It is essential that makers of 
functional foods and supplements be able to communicate the beneficial effects of their 
products on the body or health. not being able to do so means the end of such product 
concepts. It could also mean that fewer funds will be available for research in those ar-
eas, particularly if companies feel that regulators are unlikely to allow any commercial 
communications for those substances. These efSa evaluations could, therefore, be the 
beginning of the end for certain functional-food markets in the eU.  
Certain foods will be Prohibited from Claims
The first principle established by the regulation is that all claims must be approved at the 
eU level. However obtaining the authorization for a particular health claim on a specific 
substance will not be enough to ensure its use with the food formulation or product 
concept of choice. a second obstacle needs to be taken into account to determine use of 
the permitted claim on a specific product: the nutrient profile.
Nutrient Profiling
when drafting its proposal for a regulation on nutrition and health claims, the european 
Commission feared that indiscriminate use of claims by food manufacturers could lead to 
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overconsumption of “certain” food products, which could potentially contribute to the 
rising levels of obesity and diet-related diseases. It was feared also that the use of claims 
on such less nutritionally balanced products could potentially “mislead consumers when 
trying to make healthy choices in the context of a balanced diet” (regulation 9/00, 
whereas ). Therefore, as part of the objective of ensuring “a high level of protection for 
consumers,” and with the aim of avoiding the overconsumption of “certain” foods and 
consumer confusion as to what a balanced diet really is, the eU regulators introduced 
the concept of nutrient profiles in the claims regulation. nutrient profiling will be used 
as a tool to determine which foods will be “healthy enough” for claims to be made and 
which foods will be considered “unhealthy” and therefore unsuitable for claims. 
This concept has been one of the most controversial provisions of the regulation, 
leading to numerous scientific debates, political negotiations and intense lobbying by the 
food industry as well as by health and consumer non-governmental organizations. The 
main criticism raised by industry, as well as by a considerable number of nutritionists, 
against nutrient profiling is that it does not make much sense to classify individual foods 
as “healthy/good” or “unhealthy/bad.” It is acknowledged that the relevant factor in terms 
of obesity and diet-related diseases is whether the range of foods that is consumed over a 
certain period of time is sufficiently varied and balanced. This argument was also stressed 
by efSa itself, which recognized in its 00 scientific opinion on the establishment of 
nutrient profiles that “there is an inherent difficulty in seeking to apply to individual 
food products nutrient-intake recommendations that are established for the overall diet” 
(european food Safety authority, 00).
as was requested by the regulation, the Commission asked efSa for scientific advice 
on the development of nutrient profiles. However, the efSa advice remained very general, 
consisting essentially of a list of possible options on how profiles could potentially be 
developed, indicating also the respective advantages and disadvantages of each option. as 
a consequence, the profiles are being developed mostly on the basis of political negotia-
tions between the Commission and the Member-States experts, rather than on the basis 
of purely scientific arguments. This explains why the establishment of the profiles has 
been such a difficult task, and why the Commission was not able to meet the January 
009 deadline required by the regulation to establish the profiles.
The Commission tabled a first proposal in June 00, and various texts were then suc-
cessively discussed until March 009, at which time the process was put on hold when the 
political discussions reached a dramatic point: on the one hand, Member-State experts 
were seriously unhappy with the Commission’s proposals and were making too many 
requests for exemptions for specific products—considered to be of national interest!—and, 
on the other hand, various services within the Commission itself were unhappy with the 
proposals being tabled by the service in charge of the negotiations, essentially for legal 
and economic reasons. So far, the Commission has not tabled any new proposals.
although the process that will lead to the establishment of nutrient profiles in the eU 
is currently on hold, the proposals that have been discussed already give a good impres-
sion of what they will look like in the end. The Commission is focusing on three key 
nutrients: saturated fat, sodium and sugars. Different thresholds would be established 
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for these nutrients. The profiles would consist of generic thresholds for foods in general, 
expressed per 00 g or 00 mL, as well as specific thresholds for certain food categories 
that play important roles in the diet (e.g. dairy products, cereal products, meat products). 
Certain foods could be exempted from having to comply with the profiles, such as fruits 
and vegetables, food supplements, and sugar-free chewing gum. Products containing 
higher levels of saturated fat, sodium and sugars than the applicable thresholds would be 
restricted or prohibited from nutrition and/or health claims.
as was already mentioned, the development of the nutrient profiles has been essentially 
a political process with difficult negotiations on various points, including:
• what food categories should benefit from adapted thresholds?
• How should these categories be defined?
• what thresholds should apply to these categories?
• what foods should be exempted from the need for profiles?
as efSa was not asked to develop a profiling system or to propose possible nutrient 
thresholds for different food categories, this is being done by the Commission and the 
Member-State experts. Inevitably, these discussions became very political with different 
thresholds being proposed by different Member States without any apparent scientific 
justification. for example, in the discussions on the threshold that should be set for sugar 
in the category “non-alcoholic beverages,” some Member States insisted on a level of 5 
g, another proposed  g, and a few suggested 0 g, without providing any explanations 
whatsoever to justify why 5,  or 0 g would be most appropriate. 
It is clear that the food industry is not a strong supporter of nutrient profiling for 
many reasons, among which is the serious risk that nutrient profiling could hinder in-
novation—particularly in the area of product reformulations—as it will represent a clear 
disincentive for the development of healthier products within certain food categories. It 
will simply not be possible to make any claims at all (not even “reduction” claims) due to 
the strict thresholds that are being considered. However, although many legal, technical 
and scientific reasons are being put forward by industry to oppose nutrient profiling, one 
of the key reasons explaining this opposition has nothing to do with the nutrition and 
health claims. The main fear is that if a european, harmonized nutrient-profiling system, 
which would be used to identify “healthy” and “unhealthy” foods, were to be agreed by 
the Commission and the twenty-seven Member States, it would then be very difficult 
to resist calls for further restrictions and discriminations against certain food products. 
already a number of national and eU-wide campaigns are calling for restrictions, such as 
color-coded nutrition labelling (“traffic lights”), advertising restrictions and food taxation, 
that would be based on the future eU profiles.
Conclusion
although not all of the key provisions of the eU claims regulation have been imple-
mented yet, it is already possible to see its future impact on the eU market for functional 
foods, as well as on other related areas of activity such as food and nutrition research. It 
9da Silva
is now clear that the full implementation of the claims regulation will lead to a drastic 
reduction in the number of nutrition and health claims being used on the eU market. 
as a result, and taking into account the recent evaluations by efSa of some of the claim-
applications dossiers, it is fair to say that a number of product concepts, some of which 
have been successful worldwide in past years, will be facing serious challenges. Certain 
segments of the functional-foods market will be forced to reconsider their product con-
cepts, particularly in the areas of antioxidants, probiotics, low glycemic-index products, 
and herbal products. The implementation of the regulation will also lead to considerably 
less flexibility for food manufacturers and marketers to communicate to consumers the 
beneficial nutritional and health properties of certain products. Such communications 
will also be increasingly more standardized and repetitive as companies will need to keep 
their messages as similar as possible to the approved claims which, in addition, are not 
necessarily consumer-friendly.
Science will be the determining factor for success. The quality of the scientific evidence 
submitted to substantiate an application for the authorization of a health claim will be the 
essential element that will determine whether the application—and the product concept 
that would use the claim in question—has any chance of being approved. However, it must 
be stressed that it is efSa, and efSa alone, that will ultimately decide whether the data 
submitted really establish a cause-effect relationship between the substance or food and 
the claimed benefit. This should be taken into account if one intends to carry out studies 
to demonstrate the beneficial properties of certain substances. It would be worthwhile 
taking a closer look at the criteria being applied by efSa to evaluate claim-application 
files, particularly with regard to the importance given to well designed human-interven-
tion studies. finally, the potential future implementation of nutrient profiles is likely to 
have a devastating effect on a number of functional foods as associated nutrition and/or 
health claims will be prohibited. This will also have very concrete implications on funding 
opportunities for research, as no company will want to invest in research if none of its 
current and future products will be the subject of claims due to their nutritional composi-
tion. and, worryingly for industry, when such a tool that will help discriminate between 
“healthy” and “unhealthy” foods will be agreed at the eU level, the temptation for national 
and european regulators to use it for other restrictive purposes will be very real.
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